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The rate-limiting enzyme in arachidonate metabolism is mediated by enzymes known as 
cylcooxygenases (COX's). These catalyse the biosynthesis of prostaglandin H2, the precursor 
of molecules such as prostaglandins, prostacyclin and thromboxanes. The COX enzyme 
family consists of COX-I, constitutively expressed in many tissues, and COX-2, which is 
induced by stimuli such as mitogens and cytokines and is involved in many inflammatory 
reactions. Recent studies have shown increased COX-2 expression in various malignancies, 
including colorectal carcinoma, gastric carcinoma, oesophageal carcinoma, lung carcinoma 
and squamous carcinomas of the head and neck. 
Aim 
1. 	 To investigate the expression ofCyclooxygenase-2 (COX-2) in the nonnal cervix. 
2. 	 To investigate the expression ofCOX-2 in the diseased cervix. Specifically to evaluate 
expression in preneoplastic disease (cervical intraepithelial neoplasia) and invasive 
carcInoma. 
3. 	 To evaluate any association between HPV types and COX-2 expression within a 
spectrum of cervical disease. 
Methods 




















Immunohistochemical analysis for COX-2 expression was performed using a polycolonal 
anti-COX-2 antibody (sc-1745; autogen bioclear). Both the intensity and extent of COX-2 
expression were scored. 
Results and Conclusions 
1. 	 No COX-2 expression was found in the "normal" ectocervix. 
2. 	 Minimal COX-2 expression was found in the "normal" endocervix and in mononuclear 
inflammatory cells within the cervical stroma. 
3. 	 All cases ofdysplasia and carcinoma showed increased expression of COX-2. 
4. 	 The increased expression was incremental from CIN-1 through to invasive carcinoma, 
which had the highest expression. 
5. 	 COX-2 expression in dysplasia and carcinoma was highest when associated with infection 
by HPV 16 + 33 together compared to HPV 16 or HPV 33 alone. 
6. 	 There may be a role for COX-2 inhibitors in the prevention and treatment of cervical 
















CHAPTER ONE CERVICAL NEOPLASIA 

1.1 DYSPLASIA AND CARCINOMA OF THE UTERINE CERVIX 
Carcinoma of the uterine cervix is one of the leading causes ofcancer-related death in women 
world-wide and the leading cause of cancer-related death in women in South Africa [1]. The 
crude annual incidence rate of cervical cancer in 1990 - 1991 was 26/100 000 overall and 
28/100 000 in black women [2]. Given the limited resources for an effective cervical 
screening program in South Africa, and the impact ofHuman Immunodeficiency Virus (HIV), 
the incidence ofcervical dysplasia and carcinoma can be ex;pected to increase steadily. 
1.1.1 Nomenclature 
The histological classification of tumours of the uterine cervix has recently been revised by 
the International Society of Gynaecological Pathologists under the auspices of the Wodd 
Health Organization (WHO). In the WHO histologic classification, preinvasive disease is 
referred to as cervical intraepithelial neoplasia (CIN) and is graded from 1-3, which 
corresponds to mild, moderate and severe dysplasia [3]. In addition a new cervical cytologic 
nomenclature to replace the previous Papanicolaou designation has been developed, in 
accordance with the recommendations of a workshop convened by the National Cancer 
Institute in Bethesda, Maryland [4]. The generic tenn used in the Bethesda classification is 
squamous intraepitheliallesion (SIL). SIL encompasses the entire morphological spectrum of 
precursors to invasive squamous cell carcinoma, previously c~lled "dysplasia", "carcinoma­











System avoids any potential misunderstandings as to the definitions of dysplasia, carcinoma­
in-situ or neoplasia. SIL is subdivided into low-grade SIL, which corresponds to eIN 1 and 
HPV related lesions not qualifYing as CIN, and high-grade SIL, which corresponds to CIN 2 
and CIN 3. The Bethesda system recognizes that it is inherently difficult to distinguish flat 
condylomata from CIN 1 and, given the fact that most of these lesions will not progress, they 
have therefore been grouped together as low-grade SIL [5]. 
The most prevalent invasive carcinoma involving the uterine cervIX is squamous cell 
carcinoma. The WHO classification has incorporated a number of squamous carcinoma 
subtypes including: keratinzing, nonkeratinizing, verrucous, warty (condylomatous), 
papillary (transitional), and lymphoepithelioma-like. Adenocarcinoma and its subtypes form a 
separate category and then there is a group of miscellaneous epithelial tumours grouped 
together which include: adenosquamous carcinoma, glassy cell carcinoma, adenoid cystic 
carcinoma, adenoid basal carcinoma, carcinoid tumour, small cell carcinoma and 
undifferentiated carcinoma [3]. 
1.2 HUMAN PAPILLOMA VIRUS 
Human papillomavirus (HPV) has been linked to various types of cervical disease ranging 
from the relatively innocuous condyloma acuminatum to the sometimes-fatal invasive 
squamous cell carcinoma [6,7] and most likely explains the well-known association between 
sexual history (early age of first sexual contact and increased number of sexual partners) and 
increased risk of cervical cancer [7,8]. A recent study, involving 22 countries and over 1000 











14 Cervical '''''''1"'"'''' 
In 1949 Ayre [10] was the first to describe the HPV altered squamous cell subsequently 
known as a koilocyte. He originally named these cells "precancer cell complex" and 
speculated that they may be precursors to cancer. Papanicolaou described these ce]]s as 
"dyskaryotic" in his Atlas ofExfoliative Cytology and the term "koilocytosis" was introduced, 
by Koss and Durfee PI] in 1956 after the Greek word koilos (hollow). This was because of 
the cytological features characterized by the prominent, sharply defined cytoplasmic cavities 
of these ce]]s. It was two decades later that two independent groups of investigators, Meisils 
et al [12] and Sytjanen et al [13], made the connection between koilocytosis and HPV. HPV 
was initially thought to be involved in the pathogenesis of only condylomata acuminata 
although similar koilocytic changes were observed in cervical smears from women with 
cervical dysplasia and invasive carcinomas. The inability to prove a direct link between HPV 
and human neoplasia was due to the fact that HPV could not be propagated in tissue culture 
and a suitable animal model could not be found initia]]y. It was only after recent advances in 
electron microscopy (Figure 1.1), molecular biology and immunohistochemistry that the role 
ofHPV in cervical neoplasia could be appreciated [14,15]. 
1.2.1 HPV Types 
More than 80 different distinct types of HPV have been identified to date, and partial 
sequences have been obtained from more than 30 putative novel genotypes [14-16]. All 
HPV's infect the squamous epithelia of skin or mucous membranes, but different HPV 
genotypes show a specific tropism for distinct cell types. It is according to this specific 
tropism and DNA sequence homology that HPV can be divided into three categories: genital 











associated with epidennodysplasia verrucifonnis, a rare genetic cutaneous disorder 
characterized by widespread chronic nongenital HPV lesions [15,16] (Table 1.1). 
Furthennore the anogenital HPV's can be further divided into three groups based on their 
ability to induce viral associated tumours and their oncogenic potential. The high risk HPV's 
are associated with intraepithelial neoplasia that may progress to invasive anogenital 
neoplasia (1-IPV genotypes 16 and 18 most frequently detected), and the low risk HPV's are 
seen frequently in benign epithelial tumours such as condylomata acuminata and laryngeal 
papillomas (HPV genotypes 6 and 11 most frequently detected) [15,17]. Studies have lead to 
the suggestion that the high-risk group (HPV genotypes 16 and 18) be further subdivided to 
allow HPV 18 to be categorised separately. The rationale for this is that HPV 16 is found 
equally in CIN 2, CIN 3 and invasive carcinoma, whereas HPV 18 is detected much more 
frequently in invasive carcinoma than CIN [17]. 
Table 1.1 Classification of HPV Genotypes 
Genital - mucosal (anogenital) HPV Genotypes: 




Low-risk HPV genotypes: 

HPV 6, 11, 42-44, 53-55 

Moderate-risk HPV genotypes: 
HPV 33, 35, 39, 41, 52, 56, 58, 59, 68 
Nongenital (cutaneous) HPV genotypes: 

HPV 1-4,7,10,26-29,37,38, 41, 4~, 49, 65 

















A number of studies have reported the high incidence of multiple HPV infection with the 
incidence ranging from 11.6% [18] to 39.4% [19]. Mixed infections involving three or four 
HPV types are less frequent but have been noted. The prevalence of the mixed infections 
seems to vary with the severity of the lesion, with one study showing 21 % of condylomata 
and 50% ofCIN 3's having dual infections [18]. Other studies have found that a significantly 
higher proportion of double infections were detected in women with normal or inflamed 
cervices than those with CIN or invasive carcinoma [19,20]. The most common combinations, 
in cases of dual infection, are HPV types 11 and 16, 16 and 33, and 16 and 58 together. A 
number of hypotheses have been suggested to explain the apparent low risk of disease 
progression in dual infection. One such hypothesis suggests the possibility that infection of 
individual cells, by a HPV type with low transforming potential, precludes infection by a 
second virus type with greater transforming potential [19]. Another hypothesis suggests that 
for a cervical cell infected with multiple HPV types to progress to malignancy, E2 
inactivation events will have to occur in each of the existing types to avoid the E2 - encoded 
protein ofone type suppressing E61E7 proteins of the other HPV type [18,21]. 
70% of all cervical squamous carcinomas are associated with HPV types 16 or 18, and the 
remaining 30% are made up by subtypes 31, 33,35,51,52 and 58 [22,23]. In addition, HPV 
16 is more commonly associated with keratinizing squamous carcinoma compared with 
nonkeratinizing squamous carcinoma [24], and HPV 18 is more commonly associated with 
poorly differentiated carcinomas and lymph node metastases [25]. 
1.2.2 HPV Structure 
The papillomaviruses were originally grouped together with the polyomaviruses in a single 










17 Cervical Neoplasia 
genomic organization, virion size, and on different molecular patterns of replication [26,27]. 
HPV are small, nonenveloped DNA viruses, which are approximately 55nm in diameter and 
contain double-stranded circular DNA, which is covalently closed. This DNA is 7800 - 7900 
base pairs in length and packaged in a protein coat [15,28]. The DNA sequences coding all of 
the putative proteins are termed open reading frames and are all located on one DNA strand 
(Fig. 7). The non-coding regions, termed upstream regulatory regions., are located on the 
same DNA strand and promote mRNA synthesis, regulate gene expression and DNA 
replication [15,27]. 
The open reading frames are referred to as early (E) and late (L). The early region codes for 
several proteins (El - E8) which are involved in viral replication and transforming properties. 
The late region is expressed in the final phase of infection and encodes structural proteins 
involved in the assembly of viral particles [15,27,28]. 
The E2 region is thought to regulate gene expression, independently of E6, via activation of 
the tumour suppressor gene, p53 [26]. Proteins E6 and E7 stimulate cell proliferation by 
activating cyclins E and A, and interfere with the functions of tumour suppressor proteins p53 
and the retinoblastoma gene (Rb) respectively. The binding of E61E7 to p53IRb respectively 
is linked to the oncogenicity of the HPV type. For example HPV 16 and 18 show stronger 
binding compared to HPYtypes 6 and 11 [29]. 
The two "late" reading frames extend over almost half of the HPV genome and encode the 
two viral capsid proteins (Ll and L2). L1, a major capsid protein, is highly conserved 
amongst HPV genotypes whereas the L2capsid protein, a minor protein, is highly variable 
among different HPV genotypes [15,30]. In addition, the L2 protein appears to be important 










18 Cervical Neoplasia 
Figure 1.1 - Electronmicroscopic image of HPV with adjacent computer colourised image. 
Note the geometrical configuration of the outer capsid (L 1), which is composed of 72 
morphological units. The capsomers located at each of the 12 vertices, are pentavalent (i.e. 
each is surrounded by five adjacent capsomers), and the other 60 are hexavalent (each 
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Figu re 1.2 - Linear illustration of the HPV 16 genome. This is a circular arrangement of a 
single strand of DNA containg open reading frames "early"(E), and "late" (L) which are 










19 Cervical Neoplasia 
HPV typing is based on differences demonstrated by DNA hybridization, in particular 
differences in the E61E7 and Ll regions. A new HPV type is, by definition, less than 90% 
homologous with previously identified types with respect to these regions, as determined 
following complete viral cloning. A subtype shares 90 - 98 % homology in these regions and 
a variant more than 98 % homology [26,27]. 
1.2.3 HPV Life Cycle 
HPV infection of the cervix is a sexually transmitted disease and the virus life cycle is tightly 
linked to squamous differentiation. HPV must gain access to the basal epithelial cells, 
particularly those of the metaplastic squamous epithelium, for infection to occur. The alpha-6 
integrin protein has recently been suggested as a cellular receptor for HPV [31]. The virus 
may remain dormant, that is in the latent phase, for.a variable period from a few weeks to 
over 18 months, and in most individuals remains subclinical and does not produce clinically 
apparent lesions [27,31]. The viral DNA remains as a separate extrachromosomal piece of 
circular DNA, which is termed an "episome". These episomes may replicate within the 
infected cells without producing cytological atypia [30]. The transition from latent to 
productive infection is initiated by the differentiation of cells as they undergo maturation 
towards the surface. HPV types 16 and 18 have been shown to have a significantly increased 
risk of disease progression [32]. In addition, persistant viral infection with an associated high 
viral load, has also been associated with persistant cervical dysplasia [33]. At a critical point 
of epithelial differentiation, transcription of the late structural reading frames Ll and L2 
predominate resulting in viral capsid production and the formation of complete viral particles. 
Subsequently, the viral DNA becomes integrated into the host cellular genome, which is the 










20 Cervical Neoplasia 
malignant lesions characteristically show evidence of loss of L gene expression but increased 
E gene expression. The koilocytic appearance of infected cells is related to viral E4 protein 
expression, which disrupts the intracellular cytokeratin matrix facilitating the release of viral 
particles [3]. Disruption of the EI and E2 genes during viral integration allows unregulated 
expression of the E6 and E7 viral proteins, which inactivate p53 and Rb, leading to loss of 
cell cycle control and cellular transformation [30,34]. Viral DNA integration is rarely seen in 
CIN 1 (low grade cervical dysplasia), but is seen in the majority of CIN 3 (high-grade 
dysplasia) and invasive squamous cell carcinomas [35]. It is widely accepted that HPV 
infection alone is not responsible for cervical neoplasia and several cofactors for disease 
progression, including smoking [36], oral contraceptive use [37] and immunosuppression 
[38], have been implicated. It is more than likely that other cofactors, yet to be identified, do 
exist. 
1.2.4 HPV and the Immune Response 
Immunosuppressed patients are more likely to develop multiple and intractabie condylomata 
accuminata (genital warts) and are at an increased risk of developing anogenital dysplasia and 
neoplasia [27]. HIV-infected individuals have higher incidences of HPV infection (as defined 
by the presence of HPV DNA), cm, and anogenital condylomata [39]. Although no 
significant increase in the incidence of cervical cancer has been noted in this population yet, 
life expectancy for mv-infected patients has increased due to therapeutic advances, and 
cervical cancer in this group may yet become a significant health care problem. In addition 
anal cancer is found predominantly in gay men with or without concomitant mv infection 










21 Cervical Neoplasia 
risk for developing large, disabling condylomata acuminata and premalignant anogenital 
lesions due to HPV [42,43]. 
It has been established that cell mediated immune responses are crucial to the pathogenesis of 
HPV infection [44]. Regression of genital warts is characterized by .a delayed type 
hypersensitivity reaction with prominent CD4 T lymphocytes and macrophages present [45]. 
In addition, various cytokines, which are present in high concentrations, such as IL-] 2, may 
have a direct antiviral effect [46]. A recent study showed that cytotoxic T lymphocyte (CTL) 
responses to E61E7 are more commonly detectable in women with HPV 16 infection not 
associated with CIN, than in HPV 16 positive women with CIN. This suggests a possible 
protective role for the CTL response [47]. The role of humoral immunity in HPV is unclear. 
Enzyme linked immunosorbant assay (ELISA) tests using HPV 16 LIIL2 genetically 
engineered virus-like particles, have shown that recent or current exposure generates a good 
initial antibody response which then declines with time [48]. Seroconversion occurs at an 
average of eight months after cervical HPV DNA detection and the antibody persists for at 
least forty months after cervical samples become HPV negative. Not an HPV infections result 
in seroconversion with between 50% and 94% of HPV 16 infected women developing 
antibodies. Those failing to seroconvert may have less persistent infection [49]. In addition, 
HPV 16 seropositivity is associated with a 3 to 6 times increased risk of developing CIN [50]. 
1.2.5 BPV Vaccine 
HPV causes significant disease but treatment options are limited at present. The development 
of a suitable vaccine to prevent HPV -related disease is therefore essential. This is particularly 
relevant to developing countries, like South Africa, where there is a high prevalence ofHPV­










22 Cervical Neoplasia 
main objectives for a HPV vaccination programme are firstly, to prevent initial infection, 
and, secondly, to eliminate an already established infection or the infection associated with 
carcInomas. 
One difficulty in establishing a vaccine is which HPV types to include [51]. For example, 
HPV 6 and -11 constitute approximately 90% of genital condylomata acuminata, while many 
other types constitute the rest [52]. HPV 16 and -18 are found in 70% to 80% of cervical 
cancers; many other types are associated with the remainder [9]. 
In addition there are many antigenic targets for immunologic-based therapeutic agents. The 
replication proteins, Eland E2, are required to establish genital infection whereas E4 and E5 
RNA transcripts, although still of uncertain function, are the most abundant making them 
attractive targets for investigation. E6 and E7 oncoproteins are expressed during the late 
stages of disease, which also makes them possible therapeutic targets [51,53]. L1 and L2 
proteins are not always expressed late in disease limiting their usefulness as target proteins 
[53]. 
Although currently no suitable animal model is available for testing potential HPV vaccines, 
animal papillomavirusescan be used to assess critical requirements for human vaccine 
development [54]. Some animal studies have lent support for the use ofE6 and E7 proteins as 
immunological targets for new therapeutic agents [54,55]. Studies using the newly discov,ered 
canine oral papillomavirus (COPV), which causes disease on a mucosal surface and hence 
may be a better model for human disease, have shown that only native empty capsids of 
COpy are protective; denatured capsids afforded no protection [56]. Studies using a rhesus 
monkey papillomavirus, similar to the HPV types 16 and 18, have been encouraging but 
limited due to the expense of working with monkeys. Nevertheless, the rhesus monkey model 











Phase 1 and 2 trials of HPV vaccines or immunologic-based therapeutics are planned in 
humans [58]. Genital wart vaccines are being tested as the disease has a high prevalence and a 
reasonable time period to show efficacy. One method has targeted HPV-6 and -11 infections 
with either a prophylactic approach (using empty capsids) or a therapeutic approach using E7 
proteins as immunogens [59]. 
Cumulative research has shown the major capsid protein, Ll, to be the most likely antigen of 
choice. However, which HPV types are to be included and whento vaccinate are issues which 
still have to be resolved. It is essential that human trials are initiated as soon as possible for 










24 CycJooxygenase Enzymes 
CHAPTER TWO THE CYCLOOXYGENASE ENZYMES 
Cyclooxygenase (COX) or prostaglandin Hz synthase is the enzyme that catalyses the first two 
steps in the bi{)synthesis of the prostaglandins (PGs) from the substrate arachidonic acid 
(AA). These are the oxidation of AA to the hydroperoxy endoperoxide PGG2 and its 
subsequent reduction to the hydroxy endoperoxide PGHz. PGHz is transformed by a range of 
enzymes and nonenzymatic mechanisms into the primary prostanoids: PGEz, PGF2cx, PGDz, 
PGIz and TXAz [60,61] (Figure 2.1). 
Physiological 
Stimuli 
Arachidonate Inflammatory stimuli such as Cytokines and 
Growth factors ~ ~ 
NSAIDS--1 COX-1 COX-2 NSAIDS 













~ ~ C%n Tumours 
Prostaglandin H2 I 
~ ~ ~ ~ 
Figure 2.1 Synthesis of prostaglandins from arachidonate by COX-l and COX-2. 
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Since its discovery about a century ago, aspirin, and other nonsteroidal anti-inflammatory 
agents have revolutionalised the treatment of pain and inflammation associated with arthritis 
[62]. However, it was not until 1971, that the principle mechanism of action of these agents 
was discovered when Vane et al. [61] and Smith et al [63] reported that aspirin and other 
NSAIDs inhibited the COX enzyme. It was also more than 20 years ago that prostaglandins 
were reported in high concentrations in human and animal anal tumours [64]. Since these 
initial reports there has been intense investigation into the COX enzymes in an attempt to 
characterise them and hence to produce more specific treatment agents for inflammatory 
diseases i.e. arthritis. Further studies, to be discussed later, have also revealed the association 
between COX enzymes and certain malignancies. 
2.1 STRUCTURE 
PGs are short-lived substances that act as local hormones and are important in normal 
physiology and certain pathological conditions [65]. Amon&st other effects, PGs maintain 
normal gastric mucosa, influence kidney function and, via thromboxane-A2 (TXA2), aid blood 
clotting by promoting platelet aggregation [61,62,64]. In addition PGs contribute to the signs 
and symptoms of inflammation (PGE2 being the major eicosanoid detected in inflammatory 
conditions) [62]. Production of PG is initiated by phospholipase A2, which liberates 
arachidonic acid, the substrate for COx. Until the 1980's, the availability of arachidonate was 
thought to be the rate-limiting step in PG synthesis. However, the cloning of COX by three 
separate groups in 1998, and the identification of a second form of COX in 1991, revealed the 
regulatory role of these enzymes in PG synthesis [61,62,64,66]. 
The genes for COX-1 and -2 are located on chromosomes 9 and 1 respectively [61,64,67]. 
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and lq25.2-1q25.3 for COX-2 [64]. The intronlexon arrangements are identical except that 
exons land 2 ofCOX-l are condensed into a single exon in COX-2. The net result is that the 
COX-2 gene introns are smaller at 8kb whereas the COX-l introns are 22kb [67,68]. Both 
isoforms have a molecular weight of71K and are almost identical in length with just over 600 
amino acids, of which 63% are in identical sequence. The gene products also differ with the 
mRNAofCOX-l being 2.8kb and that ofCOX-2 being 4.5kb [61]. 
The three-dimensional x-ray crystalline structure of COX-2 (Figure 2.2) can be superimposed 
on that of COX-I. The residues that form the substrate binding channel, the catalytic sites, 
and the residues immediately adjacent are all identical except for two small variations at 
positions 434 and 523 (Ile exchanged for Val in COX-2). It is these two differences, which 
account for the biochemical differences between the two iso-enzymes [61,62,64]. 
Another striking structural difference between the two, but of unknown significance, is the 
absence ofa sequence of 18 amino acids at the C terminus ofCOX-2 in comparison to COX­
1. This insert does not alter the last four amino acid residues, which in both form the signal 
for attachment to the membrane of the endoplastic reticulwn (ER) [69]. However, COX-2 is 
located on the nuclear as well as the ER membrane, while COX-l is found attached only to 
the ER membrane [67,70]. Both enzymes are integral membrane proteins, but instead of 
having a transmembrane domain they are monotypic i.e. they sit within one leaflet of the lipid 
bilayer via 3 amphipathic a-helices. The COX active site is located in a channel formed in the 
centre of the membrane associated a-helices, allowing the fatty acid substrate access without 
leaving the membrane. This channel containing the active site of COX-2 seems to be more 
flexible, allowing acceptance of a broader range of substrate than COX-l [67]. These include 
a range of fatty acids including y- and a- linoleic acid. In addition specific inhibitors will 
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Figure 2.2 Ribbon structure of the basic COX enzyme. Both COX-I and COX-2 have 
identical substrate binding channels, catalytic sites and adjacent residues. They differ only at 
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2.2 NORMAL FUN CION OF COX-l & -2 
Instead of classifying PG biosynthesis into physiological and: pathological, it may be better to 
use the classification applied to COX isoforms: either constitutive (COX-I) or induced (COX­
I 
2). COX-l is constitutively expressed in nearly all cell types at a constant level 
[61,62,64,67,72,73,74]. The physiological roles ofCOX-l have been deduced by studying the 
deleterious side effects of NSAIDs. While inhibiting PG synthesis at inflammatory sites 
(COX-2), NSAIDs also inhibit constitutive biosynthesis (COX~). COX-2 is induced by most 
of the stimuli associated with inflammation including bacterial lipopolysaccharide, cytokines 
such as interleukin-l and -2 (lL-l, lL-2), and tumour necrosis factor-a. (TNF-a.) [75]. The 
COX-2 gene contains regions that allow for rapid upregulation in response to these stimuli. In 
addition the COX-2 mRNA has labile regions which result in rapid degradation and hence 
allow for rapid turnover and diminished gene expression in the absence of continued 
stimulation [75,76]. This regulation of COX-2 is seen in macrophages, synoviocytes, 
endothelial cells and chondrocytes [76]. 
2.2.1 Gastrointestinal Tract 
Cytoprotective PGs in the stomach are synthesized by COX-l and have vasodilatory effects 
enhancing mucosal blood flow. Inhibition of COX-l by NSAIDs causes gastric erosions, 
ulceration, haemorrhage and perforation [61,76,77]. In addition animal models have shown 
COX-l to be involved in epithelial regeneration within the crypts of Lieberkuhn following 
radiation injury [78]. Hence the PGs produced by COX-l appear to promote crypt stem cell 
survival and proliferation. COX-2 is not entirely absent within the gastrointestinal tract. 
Following intestinal infection, intestinal epithelial cells express COX-2, which leads to 










29 Cyc100xygenase Enzymes 
from the gut [79]. In addition, the now well established role of COX-2 in inflammation has 
implications in certain GI conditions. In tissue on the edges of ulcers, COX-2 is induced, and 
it has been suggested that blocking COX-2 may delay gastric ulcer healing in animals [SO]. 
2.2.2 Kidney 
The role ofPGs in the kidney is well established. COX-l induced production ofPGI2, PGE2 
(synthesized by both the glomerulus and medullary interstitial cells) and PGD2 diminish 
vascular--resistance by- dilating-renal- vascular bedsandenhanceorganpeffusion--[11.8-1}--This-­
in tum leads to redistribution of blood flow from the renal cortex to the nephron in the 
juxtamedullary region [S2]. NSAID blocking of COX-l leads to relative renal ischeamia. 
Animal studies have shown upregulation of COX-2 within the macula densa in salt 
deprivation states suggesting a role for COX-2 in renal sodium excretion [S3]. Thus it appears 
that the two COX isoenzymes may exert differential renal effects by synthesizing distinct 
prostanoids that react with specific receptors at different locations. These effects of the COX 
isoenzymes also appear to be intimately linked to the rennin-angiotension-aldosterone axis 
[S4]. 
2.2.3 Platelets 
Inhibition of COX-l leads to diminished fonnation of TXA2, a pivotal autocrine stimulator of 
platelet aggregation and vasoconstriction [76,S5]. This is also the therapeutic aim of "half an 
aspirin a day" prophylaxis against thromboembolic disease [S6]. Platelet adhesion is primary 
mediated by von Willebrand factor, the molecular "glue" that binds to specific receptors on 
the platelet surface localised in the platelet membrane glycoprotein Ib-lX-V complex. This 
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activates the adherent platelets and induces the release of factors that recruit additional 
platelets to the site of injury. Two important platelet-activating factors elaborated during this 
platelet release reaction are adenosine diphosphate (ADP) and thromboxane A2 (TXA2) [85]. 
NSAID inhibition of COX-l results in irreversible inhibition of TXA2 for the platelet lifetime 
of 8 - 10 days, as the platelets do not fonn new isoenzymes. Some of the new COX-2 
inhibitors do still retain some platelet TXA2 inhibitory properties but their antiplatelet potency 
is several orders lower than standard NSAIDs. This implies a minor role by COX-2 in normal 
platelet function [87]. In nonnal subjects, NSAID inhibition of COX-l has a mild clinical 
effect However, in subjects with impaired haemostasis, disruption of TXA2 becomes a 
significant problem. In patients with NSAID related gastrointestinal tract (GIT) ulceration, the 
NSAID related platelet dysfunction could bring about a potentially disastrous synergy 
resulting in severe haemorrhage [88]. 
2.2A Female Genital Tract 
PGs are important in gestation and parturition. Both COX-l and COX-2 are expressed in the 
uterine epitheliwn at different times in early pregnancy and may be important for the 
implantation of the ovwn and in the angiogenesis needed for the establishment of the placenta 
[61,89]. While COX-l related PGs appear to be involved in preparing the wall for interaction 
with the embryo, COX-2 and PG receptors seem to mediate implantation [77]. In addition the 
PGs originating from COX-2 may playa role in the birth process, since COX-2 mRNA in the 
amnion and placenta increases substantially immediately before and after the start of labour 
[77,90]. It has also been postulated that COX-2 plays a role in pretenn labour as intrauterine 
infection results in release of endogenous factors that increase PG production by upregulating 











without the side effects of indomethacin [61,91J. However, COX-2 inhibition appears to have 
little effect in preventing cervical ripening as nitric oxide appears to be the major metabolic 
mediator of this process, with COX-2 having only a minor contributing role [92]. Studies 
involving COX-2 null mice show reproductive failure at ovulation, fertilization, implantation 
and decidualization [93]. 
2.2.5 Central Nervous System 
Both COX-1 and COX-2 appear to play integral functions in the central nervous system 
(CNS) [61,77,94]. Human brain contains equal amounts of mRNA for COX-land COX-2. 
COX-1 is distributed in neurones throughout the brain, but is most prevalent in the forebrain, 
where PGs may be involved in complex integrative functions, such as modulation of the 
autonomic nervous system and sensory processing. COX-2 expression is limited to certain 
parts of the CNS, notably the cortex, hippocampus, hypothalamus and the spinal cord [95]. 
COX-2 is upregulated by normal or by abnormal (convulsive) nerve activity and is found in 
neuronal and nonneuronal cells. These findings suggest a role for PGs in CNS transmission 
and raise the possibility that selective COX-2 inhibitors may modulate CNS function [96]. 
The major PGs in the CNSare PGE2 and PGD2. Lipopolysaccharides cause the release of 
cytokines such as IL-l, which in tum induce COX-2 in brain endothelial cells. The resulting 
PGE2 then acts on the temperature-sensing neurones in the preoptic area and induce fever. 
This is also the mechanism by which NSAIDs reduce fever [61,77.,94,97]. Another central 
effect of PGs is pain or, more accurately, hyperaesthesia. COX-2 is known to be induced in 
peripheral terminals of sensory neurones with resultant PG synthesis in the setting of 
inflammatory pain [97]. Studies have also shown that NSAIDs appear to decrease by half the 
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, 
have an inflammatory component. An integral component of this disease is the fonnation of 
discrete lesions termed neuritic plaques, which contain depositions of ~-amyloid. This 
substance is thought to be elaborated as part of an inflammatory cascade involving microglial 
cells, which express COX-2 and PGs. This is postulated as a mechanism by which NSAIDs 
decrease the severity ofAlzheimers disease [61,77,96,98]. 
2.3 COX-2 AND INFLAMMATION 
As mentioned earlier, inflammatory mediators and cytokines are the main stimulus for the 
upregulation of COX-2. Initial animal studies done by Sano etal [99], and later by Anderson 
et al [100], showed increased levels of COX-2 in ipflammatory arthritis. Analysis of human 
synovial tissues in patients with rheumatoid arthritis (RA), osteoarthritis (OA) and 
nonarthritic patients with traumatic injury showed increased expression of COX-2 within the 
synovial lining. RA showed the most intense staining for COX-2, which appeared to correlate 
with the degree of mononuclear inflammation present, whereas in OA the synovial tissue 
showed less staining. Little immunoreactive COX-2 was seen in nonarthritic synovial tissues 
[67,100]. Experimental evidence has also suggested that PGE2 is intimately involved in 
mediating the inflammatory cascade with levels of COX-2 mRNA and COX-2 protein 
correlating with elevated PGE2 levels [75,76]. PGE2 is involved in the oedema of acute 
inflammation, in mediating inflammatory pain as wen as mediating chronic inflammation 
associated with arthritis [101]. 
NSAIDs are the mainstay of treatment for patients with RA and OA as well as for the 
treatment ofacute pain. In addition, more than 70% ofpeople iIi developed countries, over the 
age of 65 years, show some radiological evidence of OA and over 17 million people in the 
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companies have gone on to develop a specific COX-2 inhibitor, of which Celocoxib is one 
such example. Recent studies with Celocoxib in patients with RA and OA have shown 
excellent results in relieving pain and joint stiffness. In addition the patients suffered none of 
the unwanted side effects of COX-l inhibition such as gastric erosions, platelet dysfunction 
and renal impairment [74,101,102]. 
2.4 COX-2 AND TUMOURIGENESIS 
Evidence that arachidonic acid and its metabolites may be mediators of car.cinogenes.ts.comes 
from experimental, clinical and epidemiological studies in which inhibition of prostaglandin 
synthesis suppresses carcinogenesis. The initial work was done in colorectal carcinomas but 
other malignancies have subsequently also been studied [103]. 
Peculiar to COX-2 is its perinuclear location. One of the prostaglandin receptors, PGJ2, has 
proven to be a ligand for the retinoid X receptor family a diverse group including the 
retinoid and thyroid nuclear receptors, all acting as transcription factors for genomic DNA 
[61]. This action as a transcription factor might form the link between COX-2 activity and the 
progression of preneoplastic epithelial cells to fully malignant phenotypes [61,104]. Another 
interesting finding is an increase in BCL-2 protein, an anti-apoptotic protein, following COX­
2 activity in epithelial cells [61,67,105]. In addition enhanced synthesis of PGs, a 
consequence of upregulation of COX-2, promotes angiogenesis and inhibits immune 
surveillance, both ofwhich favour the growth ofmalignant cells [106]. 
2.4.1 Gastrointestinal Malignancies 
Initial epidemiological studies showed a lower incidence of colorectal carcino1lUl in people 










34 Cyclooxygenase Enzymes 
human colon tumours express high levels of COX-2, whereas normal intestinal mucosa has 
very little COX-2 expression [61,73,77,108]. NSAIDS also appear to reduce both the number 
and size of polyps in patients with familial adenomatosis polyposis (FAP) and hence an 
association between COX-2 and a mutation of the adenomatous polyposis coli (APC) gene 
has been postulated [61,72,73,103,108]. Another group with a clear genetic predisposition to 
colorectal carcinoma are patients with hereditary non-polyposis colorectal cancer (HNPCC) 
as they have a germline mutation in one set of genes required to repair mismatched bases in 
DNA. A recent study has shown a significantly lower level ofCOX-2 expression in colorectal 
carcinomas arising through defective DNA mismatch repair, suggesting that these carcinomas 
arise independently ofCOX-2 [109]. 
Increased COX-2 levels have also been identified in the epithelial cells ofgastric carcinoma 
[78]. The same study revealed that the degree of COX-2 expression correlated with invasion 
of lymphatic spaces and metastases to regional lymph nodes [78]. Oesophageal carcinomas, 
including both squamous and adenocarcinomas, have shown elevated COX-2 levels on both 
immunohistochemical and Western blot analysis. In vitro tests on oesophageal squamous 
carcinoma cell lines showed increased tumour cell apoptosis with selective COX-2 inhibition 
[61,110]. 
2.4.2 Head and Neck Malignancies 
Squamous cell carcinomas of the head and neck too have shown to express elevated levels of 
COX-2. Furthermore, activation of the epidermal growth factor receptor (EGFR)/ Ras 
pathway contributes to the upregulation of COX-2 and animal studies have shown that 
NSAIDS prevent head and neck squamous carcinomas [106]. 
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2.4.3 Lung Carcinoma 
Carcinoma of the lung has also shown an association with elevated COX-2 expression. This is 
particularly evident in squamous cell carcinoma and adenocarcinoma in which the COX-2 
expression correlated with the degree of tumour differentiation. Small cell carcinomas, 
however, showed only very low levels of COX-2. Of interest was the presence of elevated 
COX-2 in hyperplastic bronchial epithelium and atypical alv~olar epithelium, both considered 
to be potential preneoplastic lesions [111,112]. 
No studies have yet been reported investigating COX-2 expression in preneoplastic and 
neoplastic lesions of the uterine cervix. 
AIMS 
1. 	 To investigate the expression of cyc1ooxygenase-2 (COX-2) in the normal cervix. 
2. 	 To investigate the expression of COX-2 in the diseased cervix. Specifically to evaluate 
expression in preneoplastic disease (cervical intraepithelial neoplasia) and invasive 
carcinoma. 
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CHAPTER THREE MATERIALS AND METHODS 

In this study immunohistochemical methods were used to assess COX-2 expression in a 
range of normal and diseased cervices. These included histological normal cervices (from 
cervical biopsies and routine hysterectomies for non-cervical related disease), mild dysplasia 
(CINl), moderate dysplasia (CIN2), severe dysplasia (CIN3) and invasive squamous cell 
carcInoma. 
3.1 SELECTION OF CASES 
Cervical tissue from a total of 59 cases was obtained from archival material and recent 
routine surgical specimens. The archival material selected was limited to cases, which had 
undergone prior HPV typing using polymerase chain reaction (PCR) techniques. A 
haemotoxylin and eosin stained slide was necessary for histological diagnosis and paraffin 
wax-embedded tissue had to be available on all selected tissue in order for the 
immunohistochemical investigations to be done. In addition, cases obtained prospectively 
from the routine surgical load were subjected to PCR technique to determine HPV types. 
A total of 18 "normal" cases were selected (8 histological normal cervical biopsies from 
archival tissue, 10 routine hysterectomies for non-cervical related disease - i.e. uterine 
leiomyomas), and 41 cases incorporating a range of CIN and invasive squamous cell 
carcinoma. 
For the purposes of the study "normal" was defined as cervical epithelium not showing any 
histological evidence of dysplasia or invasive carcinoma. Underlying stromal inflammation 
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Cervical dysplasia, as described in the WHO classification; is characterised histologically by 
replacement of the normal epithelium by abnormal parabasal cells with abnormal epithelial 
maturation, nuclear atypia and abnormal mitotic figures. CIN 1 is characterised by dysplastic 
changes effecting the lower 1/3 ofthe epithelium; CIN 2 when the dysplastic changes extend 
up to involve 2/3s of the epithelium and CIN 3 when the dysplastic changes involve the 
upper 1/3 of the epithelium merging into full thickness dysplasia. In all cases, the stromal 
inflammation, when present, was scored as: 1 mild, 2 = moderate, 3 = marked. 
3.2 lMMUNOmSTOCHEMISTRY 
The antibody used in this study was kindly donated by Dr Henry Jabbour (MRC Human 
Reproductive Sciences Unit, Centre for Reproductive Biology, Edinburgh). In all cases 
studied, 3J..L sections were cut from formalin fixed, paraffin wax-embedded tissue and 
mounted onto aminopropyltriethoxysilane (APES) coated glass slides. The sections were 
dried at 56°C for 1 hour. Sections were de waxed in xylene, hydrated in graded ethanol and 
washed in water, and then blocked for endogenous peroxidases (l% H202 in methanol). 
Various heat-mediated and enzymatic digestion antigen retrieval procedures were attempted 
and included: 
(l) Antigen retrieval by means of enzymatic pre-digestion in a 0.1% porcine pancreas 
solution at 37°C at graded time intervals. 
(2) Heat-mediated antigen retrieval utilising either microwave or bench top pressure cooking 
techniques, employing a O.lM sodium citrate buffer (pH6). 
In our laboratory, heat-mediated antigen retrieval by means ofpressure cooking was found to 
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Antigen retrieval was performed by pressure cooking for 2 minutes at full pressure in O.IM 
sodium citrate (pH6). The sections were then blocked by using 5% normal rabbit serum (for 
COX-2) diluted in phosphate buffered saline (PBS). Subsequently the sections were 
incubated with polyclonal goat anti-COX-2 antibody (sc-1745; Autogenbioclear) at a 
dilution of 1:.300 at 4°C for 18 hours. Negative control tissue was incubated with either 5% 
antisera (pGE) or goat anti-COX-2 antibody preabsorbed to blocking peptide. 
After thorough washing with PBS, the tissue sections were incubated with biotinylated 
rabbit anti-goat secondary IgG antibody (for COX-2; Dako; code: E0466) at a dilution of 
1 :500 at 25°C for 40 minutes. Thereafter the tissue sections were incubated with strepavidin­

biotin peroxidase complex (Dako; code:P0364) at 25°C for 30 minutes. After washing, 





The tissue sections were then counter stained in aqueous haematoxylin followed by 





3.3 COX~2 SCORING 
No standardized scoring system for COX-2 reactivity exists. For the purpose of this study 
the following scoring system was developed. The COX~2 score was obtained for each case 
by assessing subjectively and by adding together both the intensity and the extent scores of 
the COX-2 expression. The intensity was scored out of3: 1 mild expression, 2 moderate 
expression, 3 = marked expression. The extent ofstaining was also scored out of 3: 1 focal 










39 Materials and Methods 
3.4 PCR ANALYSIS FOR HPV TYPES 
The HPV typing, utilised in thi$ study, was kindly done by Mrs. P.S. Kay in the department 
of Virology, UCT Faculty ofHealth Sciences. 
The retTospective cases used in this study had all undergone previous HPV typing using 
My09/11 Consensus Primers and subsequent Type Specific Primers (11,16,33) [113]. The 
prospective cases studied all underwent HPV typing utilizing a Restriction Fragment 
Length Polymorphisms RFLP method in conjunction with a Nested PCR method [114] 
the current method ofHPV typing done in our Virology laboratory. 
3.4.1 My09/11 Consensus PrimerslType specific primers 
DNA Extraction 
A piece ofbiopsy sample about the size of a match head was macerated in a sterile petri dish 
using a sterile disposable scalpel. Extreme caution was taken to prevent cross contamination 
of specimens. A new pair ofgloves, sterile petri dish and scalpel was used for handling each 
specimen. All work was performed in a laminar flow hood. 
DNA was extracted from the macerated biopsy sample by incubating the sample in 
proteinase K lysis buffer (50Mm KCI, 10Mm Tris-HCI Ph 8,3~ 2,5 Mm MgCh, 0,5% NP 
400,5% Triton xlOO, 120ug/ml Proteinase K) at 56°C for at least 2 hours or until no pieces 
of tissue were visible. The proteinase K was then inactivated by incubation at 95°C for 10 
minutes. The extracted DNA samples were stored at 4°C. 
Polymerase Chain Reaction using My09/11 Primers 
PCR using degenerate consensus sequence primers (Ting and Manos) was used to detect the 
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frame (ORF). PCR master mix~s were made up usmg Southern Cross Biotechnology 
reagents and Supertherm Taq. Each sample contained: 
• Reaction buffer 
• 200Um each dNTP 
• 2MmMgCh 
• 50 pmol each primer 
• 2.5 units Taq 
• Ultrapure water (BDH Ltd.) 
5ul of sample was added to 45 ul ofPCR master mix. PCR was performed in a Perkin Elmer 
GeneAmp 6700 thermocycler. After an initial denaturation step of 95°C for 3 minutes the 
samples were subjected to 30 rounds ofamplification as follows: denaturation for 30 seconds 
at 95°C, annealing for 30 seconds at 55°C and primer extension for 60 seconds at 72°C. A 
final extension step of7 minutes at 72°C was performed at the end of the cycles. 
All samples were initially amplified using PCR primers for the human CCR5 gene to ensure 
that no PCR inhibitors were present and that the sample contained amplifiable DNA Any 
samples that did not amplify with the CCR5 primers were excluded from the study. 
peR using Type Specific Primers 
Samples showing the presence of HPV DNA after amplification with the HPV consensus 
primers were then typed by PCR using type specific primers. Each sample was subjected to 
PCR using type specific primers for the following HPV types: 11, 16, and 33. 
PCR reaction mixes were made up as per MY09111 protocol except that the primers were 
changed for each type specific reaction. Cycling conditions were also the same except that 
35 PCR cycles were performed and the annealing temperatures of each type specific primer 
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• 56°C for HPV 16 type specific primers 
• 65°C for HPV 11 type specific primers 
• 65°C for HPV 33 type specific primers 
3.4.2 RFLPlNested peR 
DNA extraction. 
Biopsy samples were macerated in a sterile petri dish with a sterile disposable scalpel. 
Extreme caution was taken to prevent cross contamination of specimens. A new pair of 
gloves, sterile petri dish and scalpel was used for handling each specimen. All work was 
performed ina laminar flow hood. DNA was extracted from the macerated samples using 
the Qiagen Qiamp DNA Mini Kit. The principle ofthis procedure is as follows: 
• The macerated tissue sample is lysed using Proteinase K. 
• The buffered lysate is applied to a column. 
• The DNA is adsorbed to the silica-gel membrane. 
• The DNA is recovered from the column by elution with water. 
Detection ofHPV using group specific primers 
A nested PCR using degenerate primers, developed by Williamson and Rybicki [114] was 
used to detect the presence of HPV DNA. These primers were designed to detect a wide 
range of mucosal HPV types. The outer pair of primers is specific for a conserved 441-base 
sequence contained within the Ll gene and the inner pair of primers amplifies a 335-base 
sequence within the sequence amplified by the outer pair. PCR master mixes were made up 
using Southem Cross Biotechnology reagents and Supertherm Taq. Each reaction sample 
contained: 
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• 200uM each dNTP 
• 2mMMgCh 
• 50pmol each primer 
• 0.175 units Taq 
• Ultrapure water (BDH Ltd.) 
For the first round of amplification with the outer primers, aliquots of 45ul master mix was 
dispensed into 200ul flat topped PCR tubes and 5ul of sample DNA added. For the second 
round of amplification with the inner primers, aliquots of 49ul master mix were dispensed 
into flat topped 200ul PCR tubes and 1 ul of amplified DNA from the first round of PCR 
was added. 
PCR cycling was performed in a Perkin Elmer GeneAmp 6700 thermocycler. After an initial 
denaturation step of 94°C for 5 minutes the samples were subjected to 30 reaction cycles of 
denaturation at 94°C for 30 seconds, annealing at 45°C for 30 seconds and primer extension 
at 72°C for 1 minute. At the end ofthe cycles a final extension step of7 minutes at 72°C was 
performed. 
Before amplification with the degenerate nested primers for HPV, all samples were 
amplified using PCR primers for the human CCR5 gene to ensure that the samples contained 
amplifiable DNA and that no PCR inhibitors were present. Any samples that did not amplifY 
using the CCR5 primers were not included for amplification with the HPV primers. 
All PCR amplified products were cleaned up using the Qiagen PCR clean up kit. 
Typing of BPVs using restriction fragment length polymorphisms 
A restriction fragment length polymorphism (RFLP) method was used in conjunction with 
the nested PCR to type HPV s. The DNA sequences of known HPV types were downloaded 
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the nested PCR was mapped on the known sequences and restriction sites identified using 

DNAman. Appropriate restriction endonucleases were chosen and the RFLP was performed 





Samples were initially digested with Pst1/Bgll and BstEl1 endonucleases. The combination 

of these 2 restriction digests results in a unique pattern for HPV types 16, 33, 35 and 58. 

HPV 18 requires a further confirmatory restriction digest with Pvul1 and HPV31 with Ncol. 

The 25ul reaction mixes were made up as follows: 

• Reaction buffer 
• 2 units enzyme 
• Ultrapure water (BDH) 
• Amplified PCR product 
The reaction mixes were incubated at 37°C for 1 hour in an incubator except for the BstE 11 
digests which were incubated at 60°C. 
Electrophoresis 
After digestion the sampl s in both methodologies were electrophoresed in a 2% and 3% 

agarose gel respectively; to separate the different size framnents and these were stained with 

ethidium bromide to visualize the DNA. 














CHAPTER FOUR RESULTS 

The original haematoxylin and eosin stained sections were reviewed in all cases and the 
original histological diagnoses confirmed. The study included 18 normal controls, 4 cases of 
CIN 1,9 cases ofCIN 2, 16 cases ofCIN 3 and 12 cases of invasive squamous cell carcinoma 
(Figure 4.1). PCR analysis for HPV subtypes was available on all cases and revealed 15 cases 
negative for HPV types tested, 9 cases ofHPV 16, 7 cases ofHPV 33, 1 case ofHPV 18 and 
8 cases of HPV 16 + 33 dual infection (Figure 4.2). In addition 2 cases showed HPV 
positivity on the initial primer, but expressed too weak a signal for specific typing. 
The mean COX-2 scores for each HPV group, within each histological category, are given in 
Table 4.1 and Figure 4.3 (see page 53); and the COX-2 scores for each individual case are 
listed in Table 4.2. 
The pattern of COX-2 staining in all cases was cytoplasmic positivity and nuclear membrane 
positivity. The nucleus itself did not show any staining. 
4.1 NORMAL CERVIX 
The normal cervices consisted of 8 biopsy specimens which all showed only ectocervical 
squamous epithelium but no endocervical epithelium. The other 10 control cases were all 
obtained from elective hysterectomies for non-cervical disease and hence tissue showing both 
ecto-and endocervix. 
peR analysis for HPV was positive in 3 cases (cases 13,14,18). Case 14 was shown to 

















Figure 4.1 - Pie Chart illustrating the number of cases in each histological category. The 
small study size was due to the fact that only cases which had histological material available 
and on which HPV typing had been done, were included. The small case number precluded 
any meaningful statistical analyses. 
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Figure 4.2 - A Pie Chart illustrating the distribution of HPV typing within this study. HPV 
types 16 and 18 are categorised as "high-risk" whereas type 33 falls within the C<intermediate­
risk group. Only dual infections with a type 16 and 33 combination were found. A large 
proportion of cases (n=15) revealed no HPV on typing using the My09/11 primers. These 














11 cases showed a mononuclear inflammatory infiltrate within the underlying stroma. Case 14 
was the only 'normal' cervix to score maximum (3/3) for inflammation. 
COX-2 immunohistochemical staining showed no staining of the normal ectocervical 
squamous epithelium (Figure 4.4). All 10 cases containing normal endocervix showed basal 
COX-2 staining of both the surface and underlying glandular epithelium (Figure 4.5). The 
three cases positive for HPV showed a more intense COX-2 expression within the 
endocervical epithelium with case 14 (Figure 4.6) showing the highest COX-2 score. 
The inflammatory cells present within the stroma of all cases stained positive for COX-2 but 
no endothelial cells lining vascular spaces showed any positive staining. 
4.2 CIN 1 
Only four cases of CIN 1, where the HPV status was known, were available for inclusion in 
the study. 
PCR analysis for HPV was positive in only one case, which showed HPV 16 present. The 
other 3 cases were negative for the types tested. 
COX-2 immunohistochemical staining was positive within the dysplastic epithelium 
showing a COX-2 score range from 2.0 to 3.0. A mean COX-2 score of2.3 was present in the 
HPV negative group, and a score of3 .0 in case 22 - HPV 16 positive (Figure 4.7). 
All cases showed a stromal inflammatory infiltrate, which was positive for COX-2. Neither 












Figure 4.4 ''Normal'' ectocervix - case 16 (HPV -ve) (A) ''Normal'' cervical ectocervix 
showing an intact basal layer, normal maturation and no dysplasia. H&E, objective x 20. (8) 
COX-2 staining from the same case showing no expression by the ectocervical epithelium. 
Occasional stromal inflammatory cells show COX-2 expressIon. COX-2 
immunohistochemistry, objective x 20. 
Figure 4.5. ''Normal'' endocervix - case 16 (HPV -ve). (A) ''Normal'' endocervical columnar 
mucin secreting epithelium. H&E, objective x 20. (8) COX-2 staining of the same case 
showing weak staining in the cytoplasm around the basally located nucleus. Faint expression 











Figure 4.6 "Normal" endocervix - case 14 (HPV 18). Cervical mucosa in the region of the 
transformation zone. There is "normal" (non-dysplastic) squamous epithelium with 
underlying endocervical glands and stroma. Evidence of squamous metaplasia involving one 
gland is present (arrow). The COX-2 expression is markedly increased within the 
endocervical glands, including the gland showing squamous metaplasia. In addition, there is a 
prominent stromal inflammatory infiltrate, which also shows marked expression of COX-2. 
The changes shown here were linUted only to this case - the only "normal" case to show HPV 











4.3 CIN 2 
A total of nine cases, where the HPV status was known, showed histological features of CrN 
2. 
PCR analysis for HPV showed four cases which were negative for the HPV types tested, 
three cases were positive for HPV 33, one case positive for HPV 16 and one case showed dual 
HPV 16 and 33 positivity. 
COX-2 immunohistochemical staining was positive within the dysplastic epithelium in all 
cases. The COX-2 scores ranged from 3.0 to 4.0 with the HPV negative group showing a 
mean score of 3.0 and the HPV 33 group a mean of 3.3. Both the HPV 16 case and the case of 
dual 16 + 33 positivity showed COX-2 scores of 3.0 (Figure 4.8) . 
All cases showed a COX-2 positive inflammatory infiltrate of varying intensity, within the 
stroma. Once again no stromal cells or vascular endothelial cells showed definitive COX-2 
staining. 
4.4 CIN 3 
Sixteen cases showed histological features of CIN 3. 
PCR analysis for HPV showed six cases that were negative for the subtypes tested. There 
were three cases ofHPV 16, three cases ofHPV 33 and four cases, which showed dual 16 and 
33 positivity. 
COX-2 immunohistochemical staining was positive 10 all cases within the dysplastic 
epithelium. The COX-2 scores ranged from 2.0 to 6.0. The mean scores were 3.2 in the HPV 
negative group, 3.3 in the HPV 16 and the HPV 33 groups and 4.7 in the group showing dual 











Figu re 4.7. CIN 1 - case 22 (HPV 16) (A) Cervical epithelium showing typical features of 
CIN-I. There are dysplastic changes affecting the lower third of the epithelium with a typical 
binucleated koilocyte (centre). H&E, objective x 20. (B) COX-2 staining of the same case 
showing mild expression of COX-2 predominantly within the dysplastic lower third. Stromal 
inflammatory cells also stain with COX-2. COX-2 immunohistochemistry, objective x 20. 
Figure 4.8 CIN 2 - case 29 (HPV 33) (A) Cervical epithelium showing features of CIN 2 
characterised by dysplastic changes affecting two thirds of the epithelium with the upper third 
showing nonnal maturation. Note several atypical mitoses occurring within the dysplastic 
epithelium. H&E, objective x 20. (B) COX-2 staining of the same case showing diffuse 
staining of the dysplastic epithelium of moderate intensity. COX-2 immunohistochemistry, 











Once again a stromal inflammatory infiltrate was noted in all cases except one (case 40). No 
COX-2 staining was noted in the stromal or endothelial cells. 
Cases of CIN 3, where HPV was demonstrated, showed some variability of COX-2 staining 
intensity and extent (Table 4.2). Cases with HPV 16 or HPV 33 showed a mean COX-2 score 
of3 .3 (Table 4.1), whereas cases of dual infection with HPV 16 + 33 showed a mean COX-2 
score of 4.75 (Table 4.1). These differences are also reflected on the bar graph (Figure 4.3) 
and illustrated photographically (Figure4. -1- 1). . 
4.5 SQUAMOUS CARCINOMA 
Twelve cases showed features of squamous cell carcinoma. 
PCR analysis for HPV revealed four cases negative for the HPV subtypes tested. PCR 
showed four cases of HPV 16, one of HPV 33 and three cases of HPV 16 and 33 dual 
positivity. 
COX-2 immuDohistological staining showed a range of scores from 3.0 to 6.0. The HPV 
negative group had a mean score of 3.75, the HPV 16 group a mean of 4.25 and the HPV 33 
case scored 5.0. The group showing dual HPV 16 + 33 positivity had a mean COX-2 score of 











Figu re 4.9. CIN 3 - case 44 (HPY 16+33) (A) Cervical epithelium showing full thickness 
dysplasia. H&E, objective x 20. (B) COX-2 staining of the same case with diffuse expression 
ofCOX-2 ofa moderate intensity. COX-2 immunohistochemistry, objective x 20. 
Figure 4.10. Squamous carcinoma - case 58 (HPY 16+33) (A) Typical features of an 
invasive keratinising squamous cell carcinoma. H&E, objective x 10. (B) COX-2 staining of 
the same case showing diffuse COX-2 expression of a marked intensity. COX-2 













Figure 4.11 CIN 3 Representative sections of COX-2 expression in three different cases of 
CIN 3, each with a different HPV profile. A- case 43 (HPV 16), B- case 39 (HPV 33), C­
ease 496 (HPV 16 + 33). There is a marked increase in the COX-2 expression in the dual 











Table 4.1. Summary of the mean eOX-2 scores 
CIN 1 CIN2 CIN3 Squamous 
Ca 
HPVO 2.3 (n = 3) 3.0 (n = 4) 3.2 (n = 6) 3.75 (n = 4) 
HPV16 3.0 (n = l) 3.0 (n = l) 3.3 (n = 3) 4.25 (n = 4) 
HPV33 - 3.3 (n = 3) 3.3 (n = 3) 5.0 (n = 1) 















CIN 1 CIN 2 CIN 3 Squamous 
Carcinoma 
HPV 16 0 HPV 33 0 HPV 16+331 

Figure 4.3 Bar graph illustrating the mean eOX-2 scores for each HPV type within each 
histological group (summarised in Table 4.1). There is an incremental increase in eOX-2 
expression from eIN 1 through to squamous carcinoma. Dual infection with HPV types 16 











Table 4.2 Summary of individual case results 
number total inflam 
1 0 0 
~ LJ IIUlilidl 0 
4 b normal 0 
5 b normal 0 1 
6 normal 0 0 
7 bx normal 0 0 0 1 
8 mfu -ve normal 2-endo 3-endo 0 
9 bx -ve normal 1-endo 3-endo 1 
10 mfu -ve 1-endo 2-endo 1 
11 mfu -ve 1-endo 2-endo 2 
12 -ve 0 0 0 
13 ositive 2-endo 4-endo 1 
14 18 3-endo 5-endo 3 
15 mfu -ve 2-endo 3-endo 0 
16 mfu 1-endo 2-endo 2 
17 mfu 1-endo 2-endo 0 





cin-1 1 2 3 1 
-ve cin-1 1 1 2 1 
-ve cin-1 1 1 2 3 
16 cin-1 2 1 3 1 
2 letz -ve cin-2 2 1 R 1 . 24 lIetz -ve cin-2 2 1 1 
25 bx -ve cin-2 2 1 3 0 
26 lIetz -ve cin-2 1 2 3 1 
27 lIetz 16 cin-2 2 1 3 1 
28 bx 33 cin-2 2 1 3 1 
29 lIetz 33 cin-2 2 2 4 1 
30 lIetz 33 cin-2 1 2 3 2 











I number intensity inflamextent I totals~ hpv type •pathology 
i 32 lIetz -ve I cin-3 2 1 3 2 
I 33 lIetz I -ve I cin-3 2 1 3 1 
34 lIetz -ve cin-3 2 2 I 4 1 
35 lIetz -ve cin-3 21 1 2 









41 bx 16 cin-3 1 1 2 I 1 
42 I bx 16 cin-3 2 2 4 I ? 
43 I bx 16 cin-3 2 2 4 " 
I 44 bx 16+33 cin-3 3 2 I 5 
45 lIe12 16+33 cin-3 2 2 4 -+-i 
46 lIe12 16+33 I cin-3 3 3 6 3 
! 47 lIett 16+33 I cin-3 2 2 4 1 1 
48 bx -ve kscc 2 2 4 2 
49 bx -ve kscc 3 2 5 1 
I 50 bx -ve kscc 2 1 3 3 
51 bx -ve Icnkscc 2 1 3 1 
52 bx 16 kscc 3 2 5 3 
53 bx 16 kscc 2 2 4 1 
54 I bx 16 kscc 3 2 5 2 
55 bx 16 kscc 2 1 3 3 
56 bx 33 ~c 3 2 5 2 57 bx 16+33 3 3 6 3 
58 16+33 kscc 3 3 6 2 
59 bx 16+33 Icnkscc 3 2 5 1 
KEY: bx - biopsy, lletz lletz excision, mfu multi-fibroid uterus, ksee - keratinising 
squamous cell carcinoma, lcnkscc - large cell non-keratinising squamous cell carcinoma 
The total COX-2 score is derived by the sum of both the intensity and extent scores, and 











CHAPTER FIVE DISCUSSION 

This is the first study to examine the expression of COX-2 in the normal and diseased uterine 
cervix. In addition, this study has correlated the COX-2 expression in cervical dysplasia and 
carcinoma with specific HPV types. The absence of similar published studies does not allow 
for direct comparison of results. However, studies of COX-2 in malignancies involving other 
organ systems, particularly the GIT [103,107)09,110], lung [111,112] and head and neck 
region [106] have been reported and it is from these studies that analogies will be drawn. 
5.1 GENERAL CONSIDERATIONS 
The total number of cases of each HPV type, within each histological category, are too few 
for meaningful statistical analysis. This is due the study being limited to those cases with 
cervical pathology that had already undergone HPV typing and on which histological material 
was available. The small prospective component was done in order to obtain a "normal" 
group. This also accounted for the HPV typing having two methodologies. The retrospective 
cases had all undergone HPV typing using PCR My09/11 primers with subsequent type 
specific primers. In the last eighteen months, this method for typing has been replaced by a 
RFLP method in conjunction with nested PCR to type HPV, a method accepted as being more 
sensitive and the preferred method ofHPV typing in our Virology laboratory at present [114]. 
A proportion of the cases tested previously were negative for HPV, yet still showed 
histological evidence of dysplasia or carcinoma. It is possible that these cases harboured HPV 
types not present in the My09111 primer, which amplify a 450base pair sequence of the Ll 











present in very small quantities i.e. they may be false negative results. These cases are 
currently being re-examined for HPV using the newer method, as a HPV negative cervical 
carcinoma, in all probability, does not exist. These results are not yet available for inclusion in 
this study. 
5.2 NORMAL CERVIX 
There are no other studies describing the expression of COX-2 in the normal uterine cervix 
within the current literature. Certainly nothing is known about the role of COX-2 in the 
normal menstrual cycle particularly whether there a constant weak level of expression, or 
whether there is induced cyclical upregulation. All 18 "normal" cases studied showed 
expression of COX-2 in the histologically normal endocervical epiithelium and no expression 
in the normal ectocervix. 17 of these cases showed weak COX-2 expression within the 
cytoplasm of the endocervical surface epithelium and glands (Figure 4.4, 4.5). The level of 
expression was considerably less than that seen in the dysplastic and malignant epithelium. 
These findings in the normal cervical epitheliutl'l are similar to the COX-2 expression in the 
normal squamous epithelium adjacent to head and neck squamous carcinoma [106] and 
oesophageal carcinoma [111], where the normal epithelium adjacent to tumour showed either 
weak expression of COX-2 or no expression at alL 11 of the "normal" cases showed a stromal 
mononuclear inflammatory infiltrate which exhibited weak expression of COX-2. However 
one case, case 14, which was found to harbour HPV 18 on PCR, but which showed no 
histological evidence of dysplasia, showed a strikingly increased expression of COX-2 in the 
endocervix compared to the other "normal" cases (to be discussed in more detail in section 
5.4). In addition the stromal inflammatory infiltrate was more intense than in the other cases, 











eOX-2 in inflammatory states where studies of rheumatoid arthritis [99] and osteoarthritis 
[100] have shown that the intensity of eOX-2 staining of synovial tissue is directly 
proportional to the degree of adjacent mononuclear inflammation present. 
Some expression of eOX-2 would be expected in the normal cervix as eOX-2 does playa 
role in prostaglandin regulation in gestation and parturition [61,77,89,90,91] and it is the 
endocervical epithelium, which undergoes metaplasia and dysplasia in the development of 
cervical neoplasia. More recent studies however, have shown that the cervical PGE2 
upregulation in the pregnancy state is induced predominantly by nitric oxide a powerful 
inducer of eOX-2 - rather than by eOX-2 itself [92]. 
In addition eOX-2-induced PGE2 is intimately involved in mediating the inflammatory 
cascade [75,76]. The stromal inflammatory response present may well be induced by the viral 
activation of cytokines, which are the major mediators of increased eOX-2 activity in 
inflammatory diseases such as rheumatoid arthritis [75]. 
5.3 CIN AND CARCINOMA 
The number of cases of each HPV type, within the dysplasia and carcinoma categories, are 
too few to allow meaningful statistical analysis. However, a number of interesting trends are 
evident, even allowing that some ofthe results may be "false negatives". All cases of eIN 1, ­
2, -3, and carcinoma showed eOX-2 expression within the diseased epithelium. In addition 
there appeared to be an incremental increase in eOX-2expression from eIN 1 through to 
carcinoma as depicted by the eOX-2 scores (Table 4.1, Figure 4.3). The highest eOX-2 
scores in the categories of eIN 2, eIN 3 and invasive carcinoma were the cases showing dual 
HPV infection by types 16 and 33, with the carcinoma group showing by far the highest mean 











Several studies suggest that a dual infection involving a combination ofa low-risk and a high­
risk type is less likely to progress to a high-grade dysplasia and carcinoma [18,19,20]. 
However, the results of this study, even though limited by the small number of cases, showed 
that the cases with dual infection still progressed to CIN 3 and squamous carcinoma (Table 
4.1). Dual infection by HPV types 16 and 33, as seen in this study, represents a combination 
of a moderate-risk type (33) and a high-risk type (16) virus and may have a higher incidence 
ofprogression to CIN 3 and carcinoma than the combination of a low-risk and high-risk HPV 
type. The observation that dual infection resulted in the highest COX-2 expression, and that 
carcinoma showed more expression than the CIN cases, suggests that the amount of COX-2 
upregulation is dependent on the total viral load. It can also be deduced th~t COX-2 
upregulation must occur as a separate, eady event, in cervical carcinogenesis and has no 
direct role in interfering with the Rb protein or the tumour suppressor gene, p53. 
5.4 HPV, COX-2 AND CERVICAL CARCINOGENESIS 
COX-2 upregulation in malignancies involving the lung, oesophagus, stomach, colon and 
rectum, and head and neck region are well documented [103,106,109,110,111,112]. Similar to 
the fmdings in this study, squamous cell carcinomas in the head and neck region [106], 
oesophagus [110] and lung [111] have all shown similar upregulation ofCOX-2. Of interest is 
the observation that precursor lesions in the lung (atypical alveolar hyperplasia) and 
dysplastic lesions in the head and neck region, also showed increased COX-2 expression as 
compared to the norma] epithelium. 
Case 14, in which the cervical epithelium was histologically normal, was found to harbour 











COX-2, as discussed earlier, was far more intense than the staining seen in the HPV-negative 
"normal" cases. A1so of importance is the fact that this case showed no histological evidence 
of dysplasia, suggesting that the virus was in the episomal form. Even though these features 
are present in only a single case and no follow-up is available on this patient, it does suggest 
that COX-2 upregulation is an early event which must occur while the virus is still in the 
episomal phase and prior to the development of histologically evident cervical dysplasia. This 
finding is paralleled in studies investigating the role of COX-2 in mouse colonic adenomas 
[108] which showed that COX-2 upregulation is an early event in the colonic adenoma ­
carcinoma sequence. Furthermore it has been established that in mouse colonic adenomas, 
COX-2 expression occurs coincidentally or slightly after the loss of the wild-type APC ane]e 
suggesting a direct role ofAPC loss in COX-2 overexpression [109]. Studies looking at lung 
carcinomas and precursor lesions have found an association between K-ras oncogene activity 
and COX-2 upregulation [111]. 
Clearly there are a number of different events, in different organ systems, which result in 
COX-2 upregulation. The net effect of upregulation of COX-2 is increased PG synthesis, 
particularly PGE2, which has been shown to promote angiogenesis and inhibit immune 
surveillance [61,67,105]. It has been shown that selective inhibition ofCOX-2 in oesophageal 
cancer cells induces apoptotic cell death and reduces proliferative activity, and that these 
effects correlate with the inhibition ofPG synthesis [110]. 
Another interesting finding in a study looking at epithelial cell lines [105], is an increase in 
BCL-2 protein, an anti-apoptotic protein, following COX-2 activity. BCL-2 is associated with 
a number of different malignancies, particularly leukaemias and lymphomas, but it is also 
expressed in breast cancer, prostate cancer and lung carcinomas [115]. A recent study by 











relation to the grade of CIN. Other studies have also confinned the presence of BCL~2 
expression in cervical squamous cell carcinoma and have shown its' presence to indicate the 
likelihood of a good response to radiotherapy. [117,118,119].. Interestingly BCL~2 acts 
synergistically with a number of viruses human adenovirus, Epstein-barr virus and 
baculoviruses to inhibit apoptosis [120]. Increased expression of BCL-2 alone is almost 
certainly not sufficient to induce the tumour state, rather it promotes cell viability and thus 
allows additional genetic events to occur, the accumulative effect of which is malignant 
transfonnation [105]. BCL-2 was not part of the design of this study but will be worth 
investigating as an additional study in the future, in these and other cases. 
It is not yet clear how many factors play a role in cervical carcinogenesis. One possible 
scenario IS that COX-2 expression is induced by HPV infection of the cervical epithelium as 
an early event via inflammatory associated cytokines. Indeed, this study has shown the 
stromal inflammatory response to be increased in a case of possible episomal HPV infection. 
An elevated COX-2 level may well interact with BCL-2 or other oncogenes, such as K-ras, to 
retard the process of apoptosis. This in turn would aid the well known HPV -associated E61E7 
protein interference of p53 and the Rb gene r«suJting in the progression to cervical dysplasia 
and carcinoma. In this way COX-2 would act as a cofactor to cervical carcinogenesis. 
Current evidence suggests that our knowledge of the broad spectrum of biological activity of 
COX-2 is increasing rapidly [61,64,72] and further studies investigating potential alterations 
of specific physiological or protective mechanisms by inhibition of COX-2, are expected. It 
remains to be seen whether COX-2 inhibitors, such as NSAIDS or the COX-2 specific agents 
such as Celocoxib, have any ·effect on cervical carcinoma cell cultures or on the progression 
of cervical disease in animal models and subsequently in humans. The work to date in mouse 











human colorectal adenomas and carCInomas [103], and human epidemiological studies 
investigating the incidence of colorectal carcinoma [l07], have shown a definite therapeutic 
role for COX-2 inhibitors. Certainly more investigative work needs to be done, specifical1y 
probing for any association between COX-2 and BCL-2 or other oncogenes such as K-ras, 
and the role of cervical nitric oxide in inducing COX -2 upregulation. Studies have shovm that 
COX-2 plays an important role in pathological processes other than pain and inflammation 
and ongoing research is needed to investigate the role of specific COX-2 inhibitors in treating 
and preventing conditions such as colonic polyposis, colorectal tumours and Alzheimer's 
disease. 
5.5 CONCLUSION 
1. 	 COX-2 is expressed in small amounts in the normal cervical endocervix but not in the 
normal ectocervical squamous epithelium. 
2. 	 All cases of cervical dysplasia and carcinoma express COX-2 with the highest levels seen 
in CIN2, CIN3 and squamous carcinoma. Dual HPV infection correlated with the highest 
expression ofCOX-2. 
3. 	 Upregulation of COX-2 appears to be an early event which occurs when the HPV virus is 
still in the episomal fonn and prior to the development ofhistologically evident dysplasia. 
4. 	 The possible role of COX-2 inhibitors in the prevention and treatment of cervical 
dysplasia and carcinoma needs to be investigated further. 
In conclusion, this study has reported a possible role for COX-2 in cervical carcinogenesis. 
Further studies are needed to determine whether inhibition of COX-2 has any preventative or 
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